Chimerix Inc (NAS:CMRX)
$ 1 -0.05 (-4.76%) Market Cap: 89.63 Mil Enterprise Value: -63.91 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 55/100

Chimerix Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 13, 2019 / 06:30PM GMT
Release Date Price: $1.82 (+2.25%)
Michael A. Sherman
Chimerix, Inc. - CEO, President & Director

Good morning, everyone. Good afternoon for those on the East Coast time zone. I'm Mike Sherman, the CEO at Chimerix. I have a story to tell today about a profoundly different company than even 6 months ago. So I look forward to giving you an update on what we're doing at Chimerix.

Probably making far more forward-looking statements than my Investor Relations team would like, so let me point you to our recent SEC filings for a more complete disclosure of those risks and uncertainties.

We say we're focused on delivering real benefit to patients. I'm going to spend just a minute on that point. For those who have experienced a life-threatening disease or cancer, as I have, you'll find that you look at Kaplan-Meier curves a little differently from that side of the equation. A couple of months of progression-free survival or stable disease is not terribly interesting.

When you're talking about diseases like acute myeloid leukemia or smallpox, for that matter, it's really about getting to cures, on a higher cure rate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot